Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. [electronic resource]
Producer: 20191028ISSN:- 2379-3708
- Animals
- Antigens, Neoplasm -- administration & dosage
- Antineoplastic Agents, Immunological -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cancer Vaccines -- pharmacology
- Cell Line, Tumor -- transplantation
- Class I Phosphatidylinositol 3-Kinases
- Costimulatory and Inhibitory T-Cell Receptors -- antagonists & inhibitors
- Diphtheria Toxin -- administration & dosage
- Disease Models, Animal
- Drug Interactions
- Female
- Humans
- Lymphocyte Depletion -- methods
- Male
- Mice
- Neoplasms -- drug therapy
- Phosphatidylinositol 3-Kinases -- immunology
- Phosphoinositide-3 Kinase Inhibitors
- Purines -- pharmacology
- Quinazolinones -- pharmacology
- Signal Transduction -- drug effects
- T-Lymphocytes, Cytotoxic -- drug effects
- T-Lymphocytes, Regulatory -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.